The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder.

Section of Clinical Pharmacology, Department of Neurosciences B.B. Brodie, University of Cagliari, SS 554, km. 4,500, 09042 Monserrato, Cagliari, Italy.
Pharmacological Research (Impact Factor: 3.98). 05/2008; 57(5):369-73. DOI: 10.1016/j.phrs.2008.03.011
Source: PubMed

ABSTRACT A number of studies support the notion that lithium interacts with the protein kinase C (PKC) pathway, an important mediator of several intracellular responses to neurotransmitter signaling. PDLIM5 (PDZ and LIM domain 5; LIM) is an adaptor protein that selectively binds the isozyme PKC(epsilon) to N-type Ca(2+) channels in neurons. We tested for an association between three single nucleotide polymorphisms (SNPs) at the PDLIM5 gene and lithium prophylaxis in a Sardinian sample comprised of 155 bipolar patients treated with lithium. In order to evaluate whether PDLIM5 expression interacts with lithium response, we carried out gene expression analysis in lymphoblastoid cells of 30 bipolar patients. No association was shown between PDLIM5 polymorphisms and lithium response. When PDLIM5 expression was evaluated, no significant differences were detected between Full Responders to lithium (total score>or=7) and other patients (total score<or=6). Our negative findings do not exclude involvement of PDLIM5 in lithium prophylaxis, and further investigation is warranted.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Mood disorders have powerful effects on the lives of many people. Finding the mechanisms underlying these disorders is essential to develop selective treatment. In this thesis, interspecies trait genetics are used on behavioural domains to unravel the complex genetics of involved endophenotypes. We developed a home cage environment, allowing automated multi-day recordings, assessing the animals’ reduced preference for exposed areas (avoidance behaviour) independent of motor activity levels. To efficiently screen for genetic loci of interest, we used chromosome substitution strains (CSS) of mice; inbred strains with an A/J chromosome substituting the corresponding chromosome in the C57BL/6J background. Following behavioral testing of the full panel of chromosome substitution strains in the home cage environment, we were able to select particular strains of interest and, by the use of a F2-population, map different genetic loci specific for motor activity levels and avoidance behaviour. We genetically mapped the expression of baseline motor activity levels to mouse chromosome 1. By data mining an existing phenotypic and genotypic data set of genetically heterogeneous mice, we refined the QTL to a 312 kb interval containing a single gene (A830043J08Rik). Genome-wide microarray gene expression profiling showed a significant up-regulation of Epha4 in low active F2-individuals. Neuro-anatomical research in the spinal cord and ventral roots revealed considerable differences in motor neuron morphology, with A/J and CSS1 having smaller, possibly less developed, motor neuron axons. Also, for CSS1 and C57BL/6J, a correlation was found between motor activity levels, uncoordinated hind limb movement and neuro-anatomical differences in the cortico-spinal tract. This thesis also shows that both chromosome 15 and 19 are involved in avoidance behaviour. For chromosome 15, a small genetic region was found associated with this behavior. This QTL proved to be homologous with a human linkage region for bipolar disorder. By combining mouse SNP data with the WTCCC GWA study, 2 genes of interest were identified, showing allele frequency differences between healthy controls and bipolar patients. Only Adcy8 was differentially expressed as a function of mouse avoidance behavior in brain regions associated with mood regulation. Since Adcy8 mutant mice show altered anxiety-related behavior and the functioning of the adenylyl cyclase (AC) system is known to be changed in bipolar patients and is a target for mood stabilizers, we conclude that this gene encodes a behavioral endophenotype of bipolar disorder. Activation of AC causes the conversion of ATP to cAMP, activating (amongst others) protein kinase A (PKA). Interestingly, the QTL on mouse chromosome 19 was also found to be homologous with a human bipolar linkage region and contains genes which are functional in the PKA signaling pathway. If the changes in behavior observed in CSS15 and CSS19 are indeed caused by changes in the AC-cAMP signaling pathway, testing these and other strains in the home cage environment as described in this thesis can provide great opportunities not only to screen for other genes and cascades related to this pathway, but also to use a genetically validated model to search for effective treatment options influencing this biological signaling pathway.
  • Source
    Molecular Psychiatry 05/2009; 14(4):350-1. DOI:10.1038/mp.2008.93 · 15.15 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite continued efforts to optimize pharmacological treatment for individuals with psychiatric disorders, efficacy and tolerability of medication remains highly variable. In addition to clinical heterogeneity, diagnostic uncertainty, environmental, social factors, and genetic factors have been identified as playing an important role in the interindividual differences in therapeutic and toxic drug effects. This article describes recent developments in the field of psychiatric pharmacogenetics and focuses on antidepressant, antipsychotic, anticonvulsant, and mood-stabilizing drugs. Recent findings from pharmacogenetic clinical trials are reviewed and clinical implications are discussed. Although current data are too sparse to allow the development of guidelines for using pharmacogenetic testing in routine clinical practice, the field of psychiatric pharmacogenetics is rapidly developing and identification of genetic biomarkers that predict therapeutic response and risk of side effects will ultimately help the practitioner to choose effective and safe treatment for patients suffering from psychiatric disorders.
    Expert Opinion on Pharmacotherapy 02/2010; 11(3):423-39. DOI:10.1517/14656560903508762 · 3.09 Impact Factor